Please assess the completion status of the following clinical trial:

Trial Title: A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The study population will consist of patients with CAD undergoing PCI. Three key subgroups will be included~2. Willing and able to sign an Institutional Review Board/Ethics Committee (IRB/EC) approved informed consent prior to any study-related activities;~3. Male or female age 18 or greater;~4. If female of childbearing potential, must have a negative urine or serum pregnancy test or be post-menopausal for at least 1 year prior to randomization. Females of childbearing potential must be practicing adequate birth control to be eligible. It is the Investigator's responsibility for determining whether the patient has adequate birth control for study participation;~5. Subject is able and willing to comply with the protocol and all study procedures~Exclusion Criteria:~1. Acute ST-segment elevation myocardial infarction within 48 hours of randomization;~2. Evidence of current clinical instability~3. Evidence of a contraindication to anticoagulation or increased risk of bleeding~4. Use of any investigational drug or device within 30 days of randomization or the planned use of an investigational drug or device through EOS (Day 30 follow-up);~5. Use of the select antithrombotic agents~6. Baseline hemoglobin (Hgb) \<9 g/dL or equivalent;~7. Baseline estimated glomerular filtration rate (GFR) ≤ 10 mL/min/1.73m² or currently undergoing renal replacement therapy (hemodialysis or peritoneal dialysis);~8. Baseline platelet count \<100,000/mm3;~9. Known allergy or intolerance to aspirin, to all available ADP/P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor), or to bivalirudin or REG1 (or any of their respective components);~10. The following planned procedures: a. Planned staged PCI procedure within 3 days after randomization; b. Planned CABG or valve surgery within 30 days after randomization;~11. Any other medical or psychiatric condition that in the Investigator's judgment precludes participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bivalirudin (Type: ACTIVE_COMPARATOR): Bivalirudin bolus and infusion
- Reg 1 (pegnivacogin/anivamersen) (Type: EXPERIMENTAL): Bolus pegnivacogin plus anivamersen active control agent

Based on this trial design, predict the completion outcome and termination type (if applicable).